Treating epidermolytic ichthyosis and ichthyosis with confetti with epidermal autografts cultured from revertant skin
Open Access
- 13 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 397-404
Abstract
No efficient treatment has been established yet for epidermolytic ichthyosis (EI) caused by pathogenic variants in KRT1 or KRT10. Patients with ichthyosis with confetti (IWC) show multiple normal-appearing spots, caused by the revertant somatic recombination of pathogenic variants that occurs at each spot independently. Additionally, some patients with EI have large areas of normal skin due to revertant postzygotic mosaicism. To assess the feasibility transplanting cultured epidermal autografts (CEAs) produced from revertant epidermal keratinocytes in patients with EI and IWC. We performed a clinical trial of treatment with CEAs produced from each patient’s own revertant epidermal keratinocytes as a proof-of-concept study. This is a single-arm, open (masking not used), uncontrolled, single-assignment, treatment purpose study. The primary outcome was the rate of areas without the recurrence of ichthyosis lesions 4 weeks after the final transplant (%). The secondary outcome was the rate of areas without the recurrence of ichthyosis lesions 24 weeks after initial transplantation (%). We successfully produced CEAs from the genetically confirmed revertant skin of the two mosaic EI patients and one IWC patient and genetically confirmed that CEAs mainly consist of revertant wild-type cells by amplicon sequencing and droplet digital PCR analysis. Single-cell RNA sequencing analysis confirmed the normal proliferation and safety profiling of CEAs. CEAs were transplanted to desquamated lesional sites of the patients. Four weeks after this transplantation, the rate of areas without the recurrence of ichthyosis lesions in the three cases was 39.52%, 100.0%, and 100.0% respectively, although the recurrence of ichthyosis lesions was seen at the site of CEA transplantation in all three patients at 24 weeks after transplantation. CEAs from normal skin have the potential to be a safe and local treatment option for EI and IWC. jRCTb041190097Keywords
Funding Information
- WAS
- AMED (JP21bk0104083)
- Health (23FC1039)
- the
- Ministry of Health
- JSPS (JP21H02941)
- JST (JPMJFR210R)
This publication has 26 references indexed in Scilit:
- Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2019
- Gene Editing–Mediated Disruption of Epidermolytic Ichthyosis–Associated KRT10 Alleles Restores Filament Stability in KeratinocytesJournal of Investigative Dermatology, 2019
- A Child with Epidermolytic Ichthyosis from a Parent with Epidermolytic Nevus: Risk Evaluation of Transmission from Mosaic to GermlineJournal of Investigative Dermatology, 2017
- Revertant Mosaicism in Ichthyosis with Confetti Caused by a Frameshift Mutation in KRT1Journal of Investigative Dermatology, 2016
- Application of the cultured epidermal autograft “JACE®” for treatment of severe burns: Results of a 6-year multicenter surveillance in JapanBurns, 2016
- Successful therapeutic transplantation of revertant skin in epidermolysis bullosaJournal of the American Academy of Dermatology, 2014
- Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Sorèze 2009Journal of the American Academy of Dermatology, 2010
- Cultured epithelial autograft (CEA) in burn treatment: Three decades laterBurns, 2007
- Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patientsBurns, 2000
- GRAFTING OF BURNS WITH CULTURED EPITHELIUM PREPARED FROM AUTOLOGOUS EPIDERMAL CELLSThe Lancet, 1981